Dexmedetomidine shows promise of being an airway-stable drug. It is approved in Australia for procedural sedation. However, it is important to note that in the study on which this indication is based, all the subjects received a local anaesthetic block before their procedure or surgery. In this regard, as Health Canada has explicitly stated, further evidence still needs to be gained for the use of dexmedetomidine for procedural sedation without accompanying nerve blocks. The purpose of this current proof-of-concept, observational study is to provide further information about dexmedetomidine in three regards. First, can dexmedetomidine be used for procedural sedation per se (i.e. without local anaesthetic blocks)? Second, as opposed to results being averaged out over a wide variety of procedures, the current study examined the feasibility of dexmedetomidinebased procedural sedation for three specific procedures. Third, the current study aims to add to the pool of information regarding the appropriate dose of dexmedetomidine. As described in the dexmedetomidine product information, the Observer's Assessment of Alertness/Sedation Scale grades sedation from 5 (alert) down to 1 (deepest level of sedation). In the study on which dexmedetomidine's indication for procedural sedation is based, patients needed only to achieve a score of 4 and, thus, the approved product information recommends a loading dose of 1.0 µg/kg followed by a maintenance infusion of 0.2 to 1.0 µg/kg/hour. This current study aims to add to the literature regarding the safety of dexmedetomidine when used at higher than recommended doses.
Dexmedetomidine shows the promise of being an airway-stable drug 1 . It is approved in Australia "for sedation of non-intubated patients prior to and/or during surgical and other procedures" 2 . However, the pivotal study by Candiotti and coworkers on which this particular indication is based included patients having a wide variety of procedures in multiple surgical disciplines 1 . In particular, in that study, "all subjects received a local anesthetic block before surgery/ procedure" 1 . Health Canada has explicitly stated in regard to sedation of non-intubated patients, "Due to insufficient safety and efficacy data, Precedex™ (dexmedetomidine) is not recommended for use in procedures other than awake fibre-optic intubation and 'Monitored Anesthesia Care' with an adequate nerve block and/or local infiltration" (emphasis added) 4 .
The purpose of this proof-of-concept, observational study was to provide further information about dexmedetomidine in three regards. First, based on a study in which all patients received local anaesthetic blocks 1 , could dexmedetomidine be used for procedural sedation for noxious procedures per se (i.e. without local anaesthetic blocks) 3 ? Second, Candiotti et al averaged results across a wide variety of different procedures. In addition to the consideration of individual variation in postoperative analgesic requirements, the Procedure Specific Postoperative Pain Management (PROSPECT) group is gathering information for clinicians so that they appreciate the nuances of analgesic requirements for specific operations 5 . The same principle is worthy of consideration for the degree of stimulus for specific procedures. This study examined the feasibility of dexmedetomidine-based procedural sedation for three specific procedures: hysteroscopy, cystoscopy and transrectal ultrasound (TRUS) biopsy of the prostate. The procedures were chosen because they allow access to the airway, are relatively brief and are part of the caseload at our institution. At our institution, hysteroscopies and cystoscopies are typically performed under general anaesthesia with a laryngeal mask airway, while TRUS biopsies are performed under a propofol-based sedation regimen with a Hudson mask. We considered that, by studying three different procedures, we might increase our appreciation of which surgical stimuli are susceptible to attenuation using α-2 agonistinduced sedation because dexmedetomidine's ability to cover noxious stimuli has been questioned 6 . Third, the study aimed to augment the pool of information about the appropriate dose of dexmedetomidine. The Observer's Assessment of Alertness/Sedation Scale grades sedation from 5 (alert) down to 1 (deepest level of sedation) 2 . In the Candiotti study 1 , patients needed only to achieve a score of 4. Based on the dosing in that study, the approved product information recommends a loading dose of up to 1.0 µg/kg followed by a maintenance infusion of 0.2 to 1.0 µg/kg/ hour 2 . Anaesthetists wishing to use dexmedetomidine for procedural sedation not accompanied by local anaesthetic blocks (or who wish to achieve a deeper level of sedation than 4 on the above scale) may find the manufacturer's recommended dosing regimen inadequate 3 .
METHODS
The study was approved by the Southern Health Ethics Committee A (10098A) and was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12610000499088). This was a proofof-concept study, and a sample of convenience was taken among patients scheduled for rigid cystoscopy (excluding those scheduled for a transurethral resection of bladder tumour), hysteroscopy or TRUS biopsy. Exclusion criteria were consistent with the Candiotti study 1 except that American Society of Anesthesiologists class 4 patients were excluded.
All patients were commenced on a dexmedetomidine infusion in a fully equipped holding area separate to the operating theatre. The infusion was commenced while the theatre was being prepared after the previous case, in order to minimise delays in turnover between cases.
The initial patient was given a loading dose of dexmedetomidine 1.0 µg/kg. Depending on the degree of sedation, a reloading dose was permitted up to a nominal combined total of 1.5 µg/kg. Depending on the need for maintenance dosing requirements and dose of supplemental fentanyl given as part of the protocol, subsequent patients were to be given a higher or lower loading dose. For the loading dose, an arbitrary, pre-defined limit of 1.5 µg/kg was used. For the maintenance dose, a pre-defined limit of 1.4 µg/kg/hour was used, based on published experi-ence in an intensive care unit that gave dexmedetomidine to sedate intubated patients at up to 1.4 µg/kg/ hour 7 . After the dexmedetomidine loading dose was given, intravenous fentanyl 25 to 100 µg was given at the discretion of the supervising anaesthetist, based on each patient's individual history, comfort level, degree of sedation and respiratory rate. This dose range provided a wider dosing discretion than the 25 µg (repeated if necessary) in the Candiotti study 1 . Further doses could be given either prior to or during the procedure.
For patients having a hysteroscopy, it was left to the discretion of the individual gynaecologist whether to perform a cervical block. This was recorded. For all procedures, the protocol allowed the supervising anaesthetist to administer glycopyrrolate and/or ephedrine if deemed appropriate.
Consistent with the Candiotti study, patients remained in the recovery room for at least one hour after the discontinuation of the study drug. Discharge from the recovery room was contingent on the patients meeting standard institutional discharge criteria. The patients were also routinely assessed in the day surgery ward, post-discharge from the recovery room.
As this was a pilot study, outcome measures were deliberately limited to only a small number of broad global measures. The primary measures were (i) acceptability to surgeons: the surgeons were given a dichotomous question as to whether the operating conditions were acceptable or not in regard to performing the procedure to an acceptable standard of care; (ii) patient satisfaction: patients were asked for a global satisfaction rating regarding how satisfied they were with this method for sedation, the scale ranging from 0 (very dissatisfied) to 10 (very satisfied); (iii) need for airway intervention: all patients wore a Hudson mask and received supplemental oxygen. The dose of oxygen was not specified on the protocol and data were not collected. At our institution, oxygen is typically delivered between 6 to 8 l/minute via the Hudson mask. Patients were allowed to breathe spontaneously with no artificial airway. Any support of the airway in any manner, including touching the patient, was considered an airway intervention. Talking to the patient or asking them to take a breath was not defined as an airway intervention. The number of airway interventions and their nature was recorded. Other outcome measures included (iv) loading dose and maintenance dose of dexmedetomidine; (v) dose of fentanyl; (vi) heart rate, blood pressure and the use of drugs to support heart rate and blood pressure.
RESUlTS
A total of 20 patients were included. Ten had a hysteroscopy, six had a TRUS biopsy and four had a cystoscopy. Table 1 outlines the mean age and weight for each group.
One patient in the hysteroscopy group requested conversion to a general anaesthetic at the commencement of her procedure, after receiving the dexmedetomidine loading dose.
Of the remaining 19 who completed the study, none required an airway intervention. The surgeon rated the conditions as acceptable in 18 of the 19 completed cases. In the cystoscopy group, the surgeon rated the conditions as unacceptable in one case due to patient movement which occurred during hydro-dilation of the bladder. Table 2 shows the mean loading and maintenance doses of dexmedetomidine and mean total doses of fentanyl in the three groups. Table 3 contains the patient satisfaction and haemodynamic data.
All patients in the study received a dose of intravenous glycopyrrolate 200 µg at the discretion of the anaesthetist. Thirteen patients had an extra 200 µg dose and one a third dose. One patient was given intravenous atropine 600 µg approximately one and a half hours after the procedure. Ephedrine 3 to 6 mg was used in four patients.
DiSCUSSiON
Historically, anaesthesia and deep sedation (especially in the supine position) is associated with loss of airway tone and the need for airway instrumentation or support. if an artificial airway is needed, the level of anaesthesia must accord with that needed to instrument the airway as well as that for the level of stimulus from the procedure. Anaesthesia without loss of airway tone would potentially increase safety.
Dexmedetomidine maintains airway stability when used for procedural sedation 1 . However, evidence for its value in procedural sedation without accompanying nerve blocks is incomplete 4 , so there is a need for more data. This pilot study demonstrated that a sedation regimen of dexmedetomidine and fentanyl allowed three common procedures to be performed without airway support. The study also demonstrated airway stability after higher than recommended doses, adding to what is known about appropriate dose ranges of this drug.
As this was a pilot study, this technique cannot yet be recommended for these procedures. Nevertheless, and reassuringly, at doses up to 1.5 µg/kg loading and 1.4 µg/kg/hour maintenance, accompanied by fentanyl up to 2.4 µg/kg (in the hysteroscopy group), there was no occasion at which it proved necessary to touch or give physical support to the patient's airway, except in the sole case that was converted to a general anaesthetic at patient request.
Some issues warrant further discussion. Our protocol was consistent with the manufacturer's recommendation for the rate of the loading dose, with a 1.5 µg/kg loading dose taking 15 minutes to complete. The practicality of getting patients to theatre early and commencing the infusion under the supervision of a dedicated anaesthetist needs to be considered, especially in any economic analysis comparing this approach to traditional methods. However, human volunteer studies conducted in 1992 showed that loading doses up to 2 µg/kg given over only two minutes were well-tolerated 8 . This is ten times the rate of infusion that subjects in this study received. In our study all patients received glycopyrrolate at the discretion of the anaesthetist, and readiness to treat bradycardia may facilitate a more rapid, safe loading. Only four cystoscopies were performed. While there was high patient satisfaction (score 8.4/10), the surgeon rated the conditions as unsatisfactory for one of the procedures, due to movement during the stimulating manoeuvre of hydro-dilation of the bladder. The patient did not remember moving and gave a satisfaction score of 9/10. Further refinement and patient selection might be warranted for cystoscopy, especially if hydro-dilation of the bladder is planned.
A global satisfaction rating was used in this study. More targeted satisfaction scales could be used in the future, although we could not find specific scales to assess satisfaction with the combination of an α-2 agonist and opioid. The concomitant use of fentanyl needs to be considered. Could the same results have been achieved with either drug alone? Although dexmedetomidine is considered to possess analgesic activity, this may not be sufficient to cover noxious stimuli during a procedure. Miller's textbook Miller's Anesthesia states "In the clinical setting, when pain is likely to occur, if dexmedetomidine is to be used, the addition of a narcotic seems warranted " 6 . Fentanyl was chosen for this study based on safe administration with dexmedetomidine in the Candiotti study, although we permitted a wider dose range. In light of dexmedetomidine's questionable role as a sole agent 6 , this seemed warranted, but future research might explore higher doses of dexmedetomidine and lower doses of fentanyl. Nevertheless, we demonstrated that even at higher than the manufacturer's recommended doses of dexmedetomidine, this combination did not compromise airway stability. The dose of fentanyl used to facilitate the tolerability of noxious stimuli during the procedure may have been more than that needed for postoperative analgesia and could have contributed to excessive but not clinically concerning sedation. The supervising anaesthetist had the option to administer a dose of naloxone after the completion of the procedure and discontinuation of the study drug, providing the patient was conversing. This aspect was not prospectively defined in the study protocol and was performed as a matter of clinical care, but was not part of management in the presence of airway compromise, hypoventilation or excessive sedation. Nine patients received an average of 266 µg of naloxone and were then observed as per institutional standards. If opioids are to be used in future studies, we suggest a shorter-acting opioid such as alfentanil should be evaluated for facilitation of analgesia.
Four hysteroscopy patients received a cervical block, but the overall tolerability of this procedure is not solely dependent on blocking cervical sensory fibres 9 .
This study adds to the existing data regarding the use of dexmedetomidine (in this instance with fentanyl) at doses higher than those recommended by the manufacturer for sedation of non-intubated patients undergoing procedures.
Previous case reports describe dexmedetomidine administered in doses up to 10 µg/kg to facilitate airway surgery 10 . The data from our study contributes to that for adult sedation rather than paediatrics, where observational studies have used higher doses of dexmedetomidine in non-intubated patients. Mason and colleagues published their experience with dexmedetomidine for sedation for paediatric nuclear medicine imaging, starting with 2 µg/kg with the option to repeat the bolus twice in order to achieve a preset sedation score 11 , and for paediatric magnetic resonance imaging at up to 3 µg/kg 12 .
Recall was not a prospectively defined outcome measure so was not formally assessed. However, in general conversation after the procedure, many patients demonstrated significant amnesia for most or all of the procedure, irrespective of whether they had been conversing or following commands. Further studies might formally test the amnestic properties of dexmedetomidine at higher than recommended doses. Our protocol did not require collection of haemodynamic data after the patient had been discharged from the recovery room. That discharge required standard parameters to be met. However, the supervising anaesthetist received many calls from the Day Surgery Unit requesting clinical review of patients' blood pressure, often a significant time after the patient had left the recovery room. This observation is important for future researchers to consider.
CONClUSiON
In summary, dexmedetomidine, when given at doses higher than that recommended by the manufacturer and when combined with fentanyl, provided an airway-stable technique that allowed the performance of hysteroscopies, TRUS biopsies and cystoscopies. We recommend further investigation of dexmedetomidine as part of airway-stable anaesthesia. We recommend that future studies of higher doses of dexmedetomidine examine the postoperative course of haemodynamic changes, including after discharge from the recovery area.
